TwinBeech Capital
TGTX icon

TwinBeech Capital’s TG Therapeutics TGTX Stock Holding History

TwinBeech Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,400
Closed -$910K – 684
2026
Q1 		$910K Buy
+27,400
New +$817K 0.09% 273
2025
Q2 		– Sell
-30,756
Closed -$1.21M – 974
2025
Q1 		$1.21M Buy
+30,756
New +$1.03M 0.02% 458
2024
Q3 		– Sell
-252,823
Closed -$4.5M – 890
2024
Q2 		$4.5M Buy
252,823
+217,093
+608% +$3.46M 0.09% 241
2024
Q1 		$543K Sell
35,730
-208,258
-85% -$3.32M 0.01% 450
2023
Q4 		$4.17M Sell
243,988
-146,244
-37% -$1.7M 0.07% 297
2023
Q3 		$3.26M Buy
+390,232
New +$5.44M 0.06% 332

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

TwinBeech Capital's TGTX Position: Q2 2026 in Review

TwinBeech Capital sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 27,400 shares — an estimated $910K sold.

TwinBeech Capital first reported a position in TGTX in Q3 2023 and held it in 6 quarters. The position peaked at $4.5M in Q2 2024. 434 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • TwinBeech Capital reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TwinBeech Capital sold 27,400 TG Therapeutics shares in Q2 2026, an estimated $910K.
  • TwinBeech Capital first reported a position in TG Therapeutics in Q3 2023 and held it in 6 quarters.
  • TwinBeech Capital's TG Therapeutics position peaked at $4.5M in Q2 2024.
  • 434 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.